Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy

The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and...

Descripción completa

Detalles Bibliográficos
Autores principales: Arndt, Claudia, Fasslrinner, Frederick, Loureiro, Liliana R., Koristka, Stefanie, Feldmann, Anja, Bachmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281723/
https://www.ncbi.nlm.nih.gov/pubmed/32455621
http://dx.doi.org/10.3390/cancers12051302
_version_ 1783543985899307008
author Arndt, Claudia
Fasslrinner, Frederick
Loureiro, Liliana R.
Koristka, Stefanie
Feldmann, Anja
Bachmann, Michael
author_facet Arndt, Claudia
Fasslrinner, Frederick
Loureiro, Liliana R.
Koristka, Stefanie
Feldmann, Anja
Bachmann, Michael
author_sort Arndt, Claudia
collection PubMed
description The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and controllability of recombinant antibodies with the power of CARs. Due to their modular design, adaptor CAR systems propose answers to the central problems of conventional CAR therapy, such as safety and antigen escape. This review provides an overview on the different adaptor CAR platforms available, discusses the possibilities and challenges of adaptor CAR therapy, and summarizes the first clinical experiences.
format Online
Article
Text
id pubmed-7281723
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72817232020-06-15 Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy Arndt, Claudia Fasslrinner, Frederick Loureiro, Liliana R. Koristka, Stefanie Feldmann, Anja Bachmann, Michael Cancers (Basel) Review The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and controllability of recombinant antibodies with the power of CARs. Due to their modular design, adaptor CAR systems propose answers to the central problems of conventional CAR therapy, such as safety and antigen escape. This review provides an overview on the different adaptor CAR platforms available, discusses the possibilities and challenges of adaptor CAR therapy, and summarizes the first clinical experiences. MDPI 2020-05-21 /pmc/articles/PMC7281723/ /pubmed/32455621 http://dx.doi.org/10.3390/cancers12051302 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Arndt, Claudia
Fasslrinner, Frederick
Loureiro, Liliana R.
Koristka, Stefanie
Feldmann, Anja
Bachmann, Michael
Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title_full Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title_fullStr Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title_full_unstemmed Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title_short Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
title_sort adaptor car platforms—next generation of t cell-based cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281723/
https://www.ncbi.nlm.nih.gov/pubmed/32455621
http://dx.doi.org/10.3390/cancers12051302
work_keys_str_mv AT arndtclaudia adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy
AT fasslrinnerfrederick adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy
AT loureirolilianar adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy
AT koristkastefanie adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy
AT feldmannanja adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy
AT bachmannmichael adaptorcarplatformsnextgenerationoftcellbasedcancerimmunotherapy

Ejemplares similares